ONCY up 30% in PM on news:
Oncolytics Biotech: Data Suggest Reolysin in Combination With Gemcitabine Can Increase Median Overall Survival *Monday 07/06/2015 06:32 AM ET - Dow Jones News
Oncolytics Biotech Inc. Collaborators Present Final Data From REO 017 Clinical Study In Pancreatic Cancer *Monday 07/06/2015 06:30 AM ET - Dow Jones News
Oncolytics Biotech(R) Inc. Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic CancerMonday 07/06/2015 06:30 AM ET - PR Newswire via Dow Jones News
--Report More Than Doubling in One-Year Survival and Nearly Five-Fold Increase in Two-Year Survival as Compared to Historical Controls-- CALGARY, July 6, 2015 /PRNewswire/ - Oncolytics Biotech(R) Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Devalingam Mahalingam of the Cancer Therapy and Research Centre, University of Texas Health Science Centre San Antonio, made a poster presentation at the ESMO World Congress on Gastrointestinal Cancer. The poster, titled "Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN(R) in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma," covers final results from the Company's REO 017 Phase 2 study.
DUKE BASKETBALL and NOTRE DAME FOOTBALL
